Wilmington-based Catalyst Clinical Research has formed a partnership with a clinical operations technology firm with the goal of accelerating research and streamlining studies, according to a press release from the biotechnology company this week.
Catalyst’s oncology contract research arm will work with the ClinRub platform developed by California-based Ledger Run to “improve site budget and payment capabilities,” the release stated.
According to the announcement, this expanded partnership will allow Catalyst to use the fully integrated capabilities of ClinRun by adding contracting and forecasting solutions.
“Ledger Run is a great strategic partner for Catalyst because the company provides a unique combination of innovative technology solutions and professional services,” said Nick Dyer, CEO of Catalyst, in the release. “Their ClinRun integrated platform and first-class support has helped us overcome the operational challenges of complex oncology studies and deliver real value to our customers and investigative sites.”
Catalyst Oncology focuses on cancer therapies and provides management of immuno-oncology and therapies as well as oversight of complex studies to deliver clinical research solutions to the biotech market.
ClinRun’s software features include budgeting, contracting, payments and forecasting. It also automates manual tasks, reduces errors and speeds cycle times while promoting engagement with investigator sites, according to the release.
Catalyst has 500 full-time employees nationwide and in Europe, with many of those in the state. The company, which is made up of Catalyst Flex and Catalyst Oncology, was named one of the fastest-growing
private companies in the U.S. by the 2021 Inc. 5000 list.
In 2019, the company acquired
Wilmington-based Triangle Biostatistics, a statistical consulting and data management company for pharmaceuticals, creating a more comprehensive offering for clients, Dyer said at the time.